Introduction
Drop attacks (DA) are the most frequent and debilitating seizure types in patients with Lennox-Gastaut syndrome (LGS) and in patients affected by severe epilepsy with multiple independent spike foci (SE-MISF). Drop attacks in generalized epilepsy are hypothesized to occur as a result of activation of ''negative motor areas'' such as the rostral supplementary motor area (SMA). Pathogenetic mechanisms include atonic events, tonic contractions, massive myoclonias or a combination of these different motor phenomena. [1] [2] [3] [4] DA have a negative impact on patients' clinical and cognitive course, often determining a worsening of their quality of life. Cognitive and behavioural profile, in fact, usually decline over time in paediatric patients with disabling and drug-resistant seizures. 5 Anterior callosotomy is considered the most effective therapeutic approach in DA, leading to a seizure-free condition in 10-15% of patients. Nevertheless, there are potentially serious intra/ peri-operative events, and the possible appearance of a disconnection syndrome (or split brain syndrome), which have limited its use in childhood. [6] [7] [8] The effect of vagal nerve stimulation (VNS) on drop attacks is still controversial. Some clinical trial reported a consistent reduction in drop attacks 9 while other studies found no effect on this specific seizure type. 10, 11 Several reasons can account for these contrasting results. First, clinical studies often differ in patients' selection criteria. Second, VNS efficacy on different seizure types is not always specified. Finally, seizure outcome is often established by using different methods or classification systems.
In the present work, we tried to overcome these potential limitations by using strict criteria in patients' selection and a widely used classification system for VNS outcome. Moreover, the effect of VNS on the most disabling seizure type, i.e. drop attacks, was specifically addressed. Therefore, the major aim of this study was to evaluate long term effectiveness of VNS in two epileptic syndromes characterized by recurrent and drug-resistant drop attacks associated to other seizure types. A second aim was to evaluate VNS impact on patients' cognition, behaviour and quality of life.
Purpose: The effectiveness of VNS was evaluated in thirty-nine encephalopatic patients with drugresistant epilepsy characterized by multiple seizures and drop attacks. Twenty-five patients were affected by severe epilepsy with multiple independent spike foci (SE-MISF) and fourteen patients by Lennox-Gastaut syndrome (LGS). Method: Changes in seizure frequency, cognition, adaptive behaviour and quality of life were assessed before and after VNS implant until three years. Outcome assessment for all seizure types included the number of seizures/month and the reduction in seizure frequency rate at each follow-up. Moreover, the effect of VNS on frequency, duration and intensity of drop attacks was separately addressed by a modification of McHugh scale. Results: VNS produced a mean seizure rate reduction of 41% at six months, 50% at twelve months, and 54% at thirty-six months. After one year of stimulation, thirteen patients with SE-MISF (52%) and three patients with LGS (21%) showed a reduction above 50% in all seizures' frequency rate. As for drop attacks, eight patients (20%) gained a reduction above 50%, while seven patients (17%) showed a reduction only in intensity and duration. Cognitive level and adaptive behaviour were unchanged, while a better quality of life was reported in half out of the patients. Conclusions: VNS had a greater effect in reducing seizures frequency and drop attacks' intensity and duration in SE-MISF patients than LGS patients. An improved quality of life was observed also in those patients who only reduced the intensity and duration of drop attacks.
ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Materials and methods

Patients
The study was carried out after approval by the local Ethic Committee and according to the Declaration of Helsinki. Informed consent was obtained from all patients involved. All patients who were treated with VNS at the Regional Centre against Childhood Epilepsy (Ancona, Italy) between January 2000 and December 2008 were retrospectively reviewed. Of these patients, thirty-nine (43%) had drop attacks as a major seizure type (males: 19, females: 20, mean age at implant: 13 yrs, range: 2-51 yrs). Twenty-five patients were affected by severe epilepsy with multiple independent spike foci (Group SE-MISF) and fourteen patients by LennoxGastaut Syndrome (Group LGS). Inclusion criteria within each group were established according to International League Against Epilepsy (ILAE) (Commission on Classification and terminology of the International League Against Epilepsy, 1989). Patients classified as LGS showed atypical absences, drop attacks, tonic seizures, other generalized seizures, mental retardation, slowed electroencephalographic (EEG) background activity with awake generalized slow spike waves (2-2.5 Hz) and sleep fast rythmic activity. 1 Patients classified as SE-MISF were affected by multiple seizure types, mental retardation, and interictal multi-focal EEGs with secondary bisynchronism. 12 All patients were drug resistant, with at least five antiepileptic drugs (AEDs) being used without results. Prolonged night/day Video-EEG polygraphic recordings were carried out to assess different seizure types. Ictal EEG recordings were available for all patients. Patients with SE-MISF were previously evaluated for resective surgery, but all of them resulted inadequate. Thus, they were all submitted to VNS implantation.
Patients with LGS were submitted to VNS instead of callosotomy in accordance with the algorithm of treatment for pharmacoresistant epilepsy in use at our Centre (Fig. 1) . Patients affected by neurodegenerative or metabolic diseases and those with nocturnal apnoea or gastro-oesophageal reflux, and/or active oesophagitis were excluded from VNS implant.
Recording data
Data collection forms were designed for gathering data on the following variables: sex, age at seizure onset, type and number of seizures per month before VNS implant, number and type of AEDs before VNS implant, age at VNS implant, cognitive level and adaptive behaviour at VNS implant, duration of VNS stimulation, types and number of seizures per month after VNS implant (at 3, 6, 12, 24 and 36 months), cognitive level and adaptive behaviour after VNS implant (at 12 and 36 months), device settings and side effects.
Surgical procedure
The standard surgical procedure for VNS implant was applied, as in previous studies from our Centre. 13 
Clinical evaluation measures
During the first year of stimulation drug therapy was unchanged in order to reduce the confounding factors of drugs in outcome assessment.
Seizure frequencies at baseline were determined by asking parents to record the number of monthly seizures on a clinical 25 diary, and then averaging the number of monthly seizures relative to the last three months before the implant. Moreover, parents were asked to report both the intensity (on a five-point graduate scale from 0-very low to 5-very high) and the duration (time in seconds) of drop attacks. Clinical outcome was determined by comparing seizure frequency (i.e., the number of seizures/month) after VNS (i.e., at 3, 6, 12, 24 and 36 months) with seizure frequency during the three months pre-implantation period (baseline), by using the following formula: (seizures/month on VNS À baseline seizures/month)/(baseline seizures/month) Â 100.
Moreover, seizure outcome after twelve and thirty months of stimulation was expressed with a VNS-specific outcome scale proposed by McHugh et al. 14 This classification system includes assessment of both seizure frequency and severity (see Table 1a ).
Patients are divided into five classes according to the percentage of seizure reduction (classes I-V). The first three classes are further subdivided into two distinct sub-groups (A and B) in relation to the improvement in ictal or post ictal activity. Patients experiencing a seizure frequency reduction !50% respect to baseline (classes I and II) were considered responders. Finally, a modification of McHugh scale was used to evaluate drop attacks outcome after twelve and thirty-six months of stimulation (see Table 1b ). This modification comprised four classes: the first three classes were the same as the original version, while the fourth class was modified to highlight possible change in drop attacks' intensity and duration even if drop attacks' frequency was unchanged.
Paired sample Wilcoxon signed rank tests were used to compare seizure frequency at baseline with seizure frequency at six, twelve and thirty-six months follow-up sessions (non parametric data). Bonferroni correction was used for multiple comparisons. Moreover, differences in the frequency of responders between LGS Group and SE-MISF Group were evaluated by Chi-square test. A p value < 05 was considered statistically significant.
Cognitive, behavioural and quality of life evaluation measures
A psychological assessment was performed in three sessions: at the time of VNS implant (i.e., baseline), twelve months and thirtysix months after the implant. Assessment comprised an evaluation of cognitive level, adaptive behaviour, and quality of life (QoL), which are usually compromised in encephalopatic patients with drug-resistant epilepsy. Cognitive functioning was evaluated using the Italian version of Stanford-Binet for patients from 2 to 6 years old, and the Weschler scales for patients from 6 to 16 years (WISC-R) and above 16 years (WAIS). 15, 16 Adaptive behaviour, including four domains (communication, daily living skills, socialization, and motor skills) was measured using the Italian version of Vineland Adaptive Behaviour Scales (VABS), which provides standard scores (mean = 100, standard deviation = 15) and higher scores indicate better functioning. 17 As for the assessment of QoL, patients' parents were asked to select one of five responses along a Likertscale, according to changes observed after the implant: 5-much better, 4-better, 3-no change, 2-worse, and 1-much worse. Two experienced psychologists carried out all test and interviews, in a single blind design (i.e., assessment at the two follow-up sessions was carried out by a different investigator, who was not aware of the outcomes recorded at baseline). Paired sample Wilcoxon signed rank tests were used to compare cognitive level and adaptive behaviour scores (total score and sub-domain scores) at baseline, twelve and thirty-six months after VNS implant.
Results
Demographic and clinical data
Patients demographic are reported in Tables 2a and 2b . Overall, mean age at seizure onset was 17 months (standard deviation: 23, range: 1-117), mean age at the time of implant was 13 years (st. dev.: 8.52; range: 2-51 years) and mean duration of epilepsy before VNS was 12 years (st. dev.: 8.04; range: 2-45 years). After VNS patients were followed for at least thirty-six months (range: 36-98 months). Epilepsy was classified as cryptogenic in thirteen cases and symptomatic in twenty-six. Among symptomatic patients, bilateral cortical dysplasia was the most common aetiology (44% of patients). Drop attacks were the main seizure type, with daily frequency in thirty-six cases (92%). They were atonic in seventeen patients (44%) and tonic in twenty-two patients (56%). Atonic DA were present in most of patients with LGS (11/14,79%) and in half of patients with SE-MISF (11/25, 44%). Other seizure types were present in patients affected by SE-MISF, mostly complex partial seizures (CPS) and partial seizures with secondary generalization (PSSG). Three of these patients required frequent hospitalization in Intensive Care Unit for prolonged status epilepticus. As for patients affected by LGS, the most frequent seizure types were spasms, atypical absences and tonic seizures. The interictal EEG of patients with LGS showed generalized anomalies and background activity, while in SE-MISF patients EEG recordings showed multi-focal abnormalities (frontal abnormalities in 2/3 of cases) with secondary bisynchronism. The two groups did not significantly differ in the following variables: mean age at seizure onset (SE-MISF: 16 AE 31, LGS: 19 AE 31) mean age at implant (SE-MISF: 13.42, LGS: 13.84), mean number of AEDs (SE-MISF: 3.04;
LGS: 3.14), mean duration of epilepsy before the VNS implant (SE-MISF: 12.07; LGS: 12.39), mean number of seizures/month before the VNS implant (SE-MISF: 306 AE 308; LGS: 302 AE 230, p > .3 in all comparisons). No intra and perioperative complications occurred and no patients showed bradycardia or any infections during the postoperative period. Chronic side effect stimulation related were mild, transient, without clinical relevance. At the last follow-up, only one patient asked for device removal because of subjective intolerance and lack of a clinical response. In three cases, the stimulator was turned OFF because ineffective in controlling seizures.
Clinical outcomes 3.2.1. All seizure types
Seizure outcomes are summarized in Tables 2a and 2b and Figs.  2 and 3 . As a whole, a significant reduction of the total number of seizures/month was observed after VNS. Compared to baseline (mean: 304; standard deviation: 278, range: 10-1200), mean number of monthly seizures was 178 AE 176 at six months after the implant (p < .0001) 155 AE 159 at twelve months (p < .0001), and 140 AE 174 at thirty-six months (p < .0001). No significant differences were observed between six, twelve and thirty-six months. However, a slight, progressive reduction in seizure frequency was observed over a period of three years. Both groups gained a significant reduction in seizure frequency after VNS (p < .05 in all comparisons, see Fig. 2a ). However, SE-MISF patients showed a lower number of seizures/ months at each follow-up session compared to LGS (p < .05).
All together, VNS produced a mean seizure rate reduction of 41% at six months, 50% at twelve months, and 54% at thirty-six months. After one year of stimulation seizure outcome was rated as McHugh's class I (80-100% reduction in seizure frequency) in four patients (LGS: 1; SE-MISF: 3), class II (50-79%) in twelve patients Table 2b Clinical and demographic data of patients affected by LGS.
Pz no./gender [ ( ) T D $ F I G ] [ ( ) T D $ F I G ] (LGS: 2, SE-MISF: 10), class III (<50%) in fourteen patients (LGS: 7, SE-MISF: 7), and class V (no improvement) in nine patients (LGS: 4, SE-MISF: 5). No one experienced benefit by manually activating the VNS with a magnet (class IV). Moreover, two patients from SE-MISF were seizure-free. Two out of the three patients who experienced Status Epilepticus (SE) before VNS (P7, P24) showed no more SE after the implant, while one patient (P23) had one episode after one year of stimulation. Frequency of responders (seizure reduction equal or above 50%) was significantly higher in the SE-MISF Group (52%) than LGS Group (21%) (p < .01). The number of responders remained the same after thirty-six months of VNS. Postoperatively, the number of AEDs was unchanged in all patients.
Drop attacks
As for drop attacks, two patients had a reduction between 80 and 100% (class I; SE-MISF: 2; LGS: 0), and six patients showed a reduction of drop attacks between 50% and 79% (Class II; SE-MISF: 4, LGS: 2). Overall, eight patients (20%, SE-MISF: 6, LGS: 2) showed a reduction in DA equal or above 50% (classes I and II), whereas seven patients (17%, SE-MISF: 7, LGS: 1) showed no change in the number of drop attacks but presented a significant reduction in their intensity and duration (class IV) (see Table 3 ). No effect of VNS on DA was obtained in more than half of patients (62%). The frequency of patients who experienced a reduction in DA equal or above 50% was not significantly different between the two groups (SE-MISF: 20%, LGS: 14%, p > .1). However, the frequency of patients who gained a reduction only in intensity and duration was significantly higher among SE-MISF (29%) than LGS (7%, p < .05). Finally, no significant difference in the frequency of responders were observed between patients with atonic (32%) and tonic DA (47%, p = .2). The clinical outcome for DA was stable over time without significant variations after the first year following the implant.
Cognitive and behavioural outcome
Mental retardation was observed in all patients before VNS implant (i.e., baseline). This was moderate in five patients (SE-MISF: 5; LGS: 0) and severe in thirty-four patients (SE-MISF: 20;
LGS: 14). Among patients with severe mental retardation, those affected by LGS were more frequently represented (100%) than SE-MISF (80%). Moreover, adaptive behaviour was more compromised in LGS (VABS standard score <50) than SE-MISF (VABS standard score between 50 and 65). Compared to baseline, after one year and three years of stimulation, no significant changes in cognitive level and adaptive behaviour scores were observed in both groups (p > .2). By looking at each patient individually, no decline in cognitive level was found. Moreover, twelve patients (LGS: 4; SE-MISF: 8) experienced a clinically relevant improvement in adapting behaviour (increase of at least five points in standard scores), which was mainly due to an increased alertness and a better social reciprocity. Finally, a better QoL (mean score: 4.2) was reported in half out of patients (SE-MISF: 13; LGS: 6) while the other half reported no change. It is worth noting that an improvement in QoL after VNS was observed regardless of seizures' outcome.
Discussion
In the last ten years, VNS has become the first choice treatment for a wide number of intractable epileptic syndromes. 18, 19, 13 The mechanism for seizure control with VNS is, in general, not well understood, but may involve desynchronization of synaptic activity, decreased activity of limbic structures, and release of norepinephrine. 20 Existing series on VNS for drop attacks are limited by small number of patients 21 and short follow-up, 22 or have addressed outcomes specific to drop seizures only indirectly. 20 In the present study, we have described two cohorts of patients affected by Lennox-Gastaut syndrome (LGS) and severe epilepsy with multiple independent spike foci (SE-MISF), who presented drop attacks as the most disabling seizure type, and were treated with VNS for a minimum of three years.
Forty-six percent of patients experienced a reduction of all seizure types above 50% after one year of stimulation, which maintained stable after three years. Results from different case series reported in the literature have shown an extremely variable reduction in seizure frequency after VNS (between 15% and 70%), which may be due to differences in patients' selection criteria and outcome assessment. 8, 10, 11, 13, 18, 20, 21, 23, 24 In our cohorts, the frequency of responders was significantly higher in patients affected by SE-MISF than LGS at each follow-up session, so suggesting a reduced efficacy of VNS in LGS compared to SE-MISF. This result is in line with a recent study, showing that patients with SE-MISF had better percentage seizure reduction compared with LGS. 25 It is worth noting that both groups showed the same seizure frequency at baseline and no significant differences in demographic and clinical variables, which may explain the difference in seizures' outcome. Other studies have shown the lack of significant correlations between seizure frequency reduction after VNS and duration or type of epilepsy. 26 Moreover, a progressive improvement in seizure frequency was observed after VNS over a period of three years. It is known that some patients can exhibit a delayed response to VNS, which may be due to a cumulative effect of stimulation over time. 25, 26 As for drop attacks, eight patients (20%) showed a reduction greater than 50%, whereas seven patients (17%) showed no change in the number of drop attacks but presented a significant reduction in their intensity and duration. Despite these last patients did not obtain any reduction in drop attacks' frequency, the presence of slower and less severe falls was associated to a better quality of life. Also in this case, the frequency of patients who gained a reduction in drop attacks' intensity and duration was significantly higher among SE-MISF than LGS.
Contrasting results have been reported for drop attacks in the literature. A consistent reduction (88%) was observed in a group of fifty young patients affected by LGS after 6 months of VNS. 27 These results are quite different from the outcome observed in LGS patients from the present case series, who gained a drop attacks' reduction around 15% after six months and one year of stimulation. In a study by Shahwan et al., a disappearance of drop-attacks was observed only in two out of nine patients with LGS, while in the present case series none of the fourteen patients with LGS was seizure-free. 28 However, two patients with LGS showed a reduction in DA between 50 and 75%, and one patient reported a consistent reduction in intensity and duration. A recent retrospective analysis of forty-three pediatric patients with drop attack seizures found that on last follow-up, 46% of patients had at least a 75% reduction in drops per day. 9 This outcome seems far better than the one observed in our case series. However, since diagnosis was not specified for most of those patients, it is hard to compare the two studies. Moreover, nearby all patients who experienced a consistent reduction in DA (>75%) showed focal epileptiform discharges at baseline. By contrast, in the present case series all patients had multifocal discharges, which might explain, at least in part, the lesser response to VNS. All patients in the present case series had some degree of mental retardation, which might have been due in some part to seizures. It is known that patients with epileptic encephalopathy may experience a deterioration of adaptive skills along time, if no intervention is carried out. 29 The cognitive and behavioural profile of our patients did not significantly modify after VNS. However, due to the severity of the psychological profile at baseline, especially evident in LGS, the absence of a cognitive decline should be considered as a positive outcome. Moreover, one third of patients improved their adaptive behaviour, and half out of patients reported a better quality of life, regardless of epilepsy severity. It is worth noting that the lack of a control group did not allow us to clearly determine the real effectiveness of VNS in the present study. This limitation should be overcome in future research.
Conclusion
VNS was effective in reducing the total number of seizures in encephalopatic patients with drug-resistant epilepsy, leading to a better management of seizures at home and to a reduced number of hospitalizations along time. This treatment showed a greater effect in reducing both seizure frequency and drop attacks' intensity and duration in SE-MISF patients than LGS patients. A possible explanation for this result needs to be addressed in future research. Moreover, an assessment of drop attacks' intensity and duration, other than seizure frequency per se, should be recommended in clinical outcome evaluations. Despite callosotomy is the most effective therapeutic approach for DA, VNS should be considered as a first-line therapy because it is less invasive, has a lower risk of adverse effects, and is effective in reducing additional seizures types (other than drop attacks). Moreover, compared to callosotomy, VNS better preserves cognitive profile and improves alertness and social skills in some patients. However, in cases in which VNS is ineffective in reducing drop attacks, callosotomy should be considered as a second-line option.
